Last10K.com

Logicbio Therapeutics, Inc. (LOGC) SEC Filing 8-K Material Event for the period ending Tuesday, July 2, 2019

Logicbio Therapeutics, Inc.

HISTORY TOOLS
CIK: 1664106 Ticker: LOGC

View differences made from one to another to evaluate Logicbio Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Logicbio Therapeutics, Inc..

Continue

Assess how Logicbio Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Logicbio Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Material Contracts, Statements, Certifications & more

Logicbio Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 4.1: Instruments Defining The Rights Of Security Holders, Including Indentures
Exhibit 10.1: Material Contract
Exhibit 99.1: Additional Exhibits
Ticker: LOGC
CIK: 1664106
Form Type: 8-K Corporate News
Accession Number: 0001193125-19-188256
Submitted to the SEC: Tue Jul 02 2019 4:22:33 PM EST
Accepted by the SEC: Tue Jul 02 2019
Period: Tuesday, July 2, 2019
Industry: Biological Products No Disgnostic Substances
Events:
  1. Financial Exhibit
  2. New Agreement
  3. New Financial Obligation
  4. Unregistered Sales

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/logc/0001193125-19-188256.htm